Cyclin dependent kinase inhibiting purine derivatives
CA 2294244 A1 · Owner: Boyle, Francis Thomas · Inventors: Noble, Martin Edward Mantyla; Curtin, Nicola Jane; Boyle, Francis Thomas
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
A range is disclosed of purine derivatives (I) which can act as inhibitors of cyclin dependent kinases (CDKs) and which thereby c an provide useful therapeutic compounds for use in treatment of tumours or other cell proliferation disorders. The compounds of this invention bind to CDK molecules in a manner that appears to be different to that of known CDK inhibitors such as olomoucine and roscovitine. In formula (I) in preferred embodiments: X is , O, S or CHRx where Rx is H or C1-4 alkyl; D is H halo or NZ1Z2 where Z1 and , Z2 are each independently H or C1-4 alkyl or C1-4 hydroxyalkyl; A is selected from H, C1-4 alkyl, C1-4 alkoxy, hydroxy CH2(CH2)nOH (n=1-4), and NRa1Ra2 , where Ra1 …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed July 10, 1998. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended July 10, 2018.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by July 10, 2020.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.